This presentation includes certain disclosures that contain "forward-looking statements" intended to qualify for the "safe harbor" from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding our beliefs and expectations regarding the advancement of our oncology and COVID-19 therapeutic antibody programs, execution of our regulatory, clinical and strategic plans, anticipated upcoming milestones for IMM-BCP-01 and IMM-ONC-01, including expectations regarding therapeutic potential and benefits thereof, and IND filings. Forward-looking statements may be identified by the words "anticipate," believe," "estimate," "expect," "intend," "plan," "project," "may," "will," "could," "should," "seek," "potential" and similar expressions. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business, operations, strategy, goals and anticipated milestones; our ability to execute on our strategy with respect to our R&D efforts, IND submissions and other regulatory filings, timing of these filings and governmental authority feedback regarding the same, initiation of clinical studies, generation of clinical data and other anticipated milestones as and when anticipated; the effectiveness of our product candidates, including the possibility that further preclinical data and any clinical trial data may be inconsistent with the data used for advancing the product candidates; our ability to fund operations; our reliance on vendors; the competitive landscape; and the additional risks and uncertainties set forth more fully under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 25, 2021, and elsewhere in our filings and reports with the SEC. Forward-looking statements contained in this document are made as of this date, and we undertake no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.
This document may contain product names, trade names, trademarks and service marks of the Company and of other organizations, of which are the properties of their respective owners.
Statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of
the date of this presentation, including independent market research, industry publications and surveys, governmental agencies and publicly available information. While we believe that information provides a reasonable basis for these statements, it may be limited or incomplete and we may have not independently verified it. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review or verification of, all relevant information.
We may make statements about estimated dates for milestones related to our programs. Estimates involve risks and uncertainties and are subject to change based on various factors and evolution over time.
In this presentation and oral commentary, we may discuss our current and potential future product candidates that have not yet undergone clinical trials or been approved for marketing by the U.S. Food and Drug Administration or other governmental authority. No representation is made as to the safety or effectiveness of these current or potential future product candidates for the use for which such product candidates are being studied. This presentation does not constitute an offering of securities of any kind.
Experienced Management Team
Purnanand Sarma, PhD
Former CEO of Taris Biomedical
President & CEO
Sold to Johnson & Johnson in 2019
Former US CFO Biogen
Chief Financial Officer
Former CFO, Global Vaccines, Wyeth/Pfizer
Dennis Giesing, PhD
Former CSO at Taris Biomedical
Led BARDA funded pandemic flu program at MediVector
Immunome Inc. published this content on 21 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 September 2021 14:41:02 UTC.